

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: AP2/20 - Antithrombotic Agents

Deadline: 18.09.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Set 1</b>														
<b>(108) Apixaban</b>					30							30	29	97%
Samples and groups		[µg/L]												
<b>Sample A1</b>						CVP								
(38) IL		207	21	10	30		207	9,4	25%	155	259	30	30	100%
(94) Stago		224	14	6,2	8	0						8		
(193) HYPHEN BioMed		207	3,0	1,4	6	0						6		
Other		197	22	11	12	0						12		
					4	0						4		
							2x 149, 2x 179							
<b>Sample B1</b>						CVP								
(38) IL		406	27	6,5	30		406	12	25%	304	508	30	29	97%
(94) Stago		429	14	3,3	8	0						8		
(193) HYPHEN BioMed		405	18	4,4	6	0						6		
Other		390	28	7,3	12	0						12		
					4	0						4		
							2x 149, 2x 179							
<b>Set 2</b>														
<b>(109) Dabigatran</b>					33							33	30	91%
Samples and groups		[µg/L]												
<b>Sample A2</b>						CVP								
(38) IL		103	16	16	33		103	6,9	25%	77,2	129	33	30	91%
(193) HYPHEN BioMed		103	12	12	11	0						11		
Other		112	17	15	15	0						15		
					7	0						7		
							1x 94, 4x 149, 2x 179							
<b>Sample B2</b>						CVP								
(38) IL		295	32	11	33		295	14	25%	221	369	33	33	100%
(193) HYPHEN BioMed		292	29	10	11	0						11		
Other		311	27	8,7	15	0						15		
					7	0						7		
							1x 94, 4x 149, 2x 179							
<b>Set 3</b>														
<b>(110) Rivaroxaban</b>					36							36	36	100%
Samples and groups		[µg/L]												
<b>Sample A3</b>						CVP								
(38) IL		95,5	12	13	36		95,5	5,1	25%	71,6	120	36	36	100%
(94) Stago		95,7	8,2	8,6	10	0						10		
(193) HYPHEN BioMed		81,0	5,9	7,3	6	0						6		
Other		102	13	13	15	0						15		
					5	0						5		
							2x 149, 3x 179							
<b>Sample B3</b>						CVP								
(38) IL		283	28	9,9	36		283	11	25%	212	354	36	36	100%
(94) Stago		254	9,9	3,9	10	0						10		
(193) HYPHEN BioMed		274	11	4,1	6	0						6		
Other		300	17	5,5	15	0						15		
					5	0						5		
							2x 149, 3x 179							

st\_kn\_p

End of report

Printed: 24.09.2020